174 related articles for article (PubMed ID: 34689785)
1. MYCN and MAX alterations in Wilms tumor and identification of novel N-MYC interaction partners as biomarker candidates.
Jiménez Martín O; Schlosser A; Furtwängler R; Wegert J; Gessler M
Cancer Cell Int; 2021 Oct; 21(1):555. PubMed ID: 34689785
[TBL] [Abstract][Full Text] [Related]
2. Multiple mechanisms of MYCN dysregulation in Wilms tumour.
Williams RD; Chagtai T; Alcaide-German M; Apps J; Wegert J; Popov S; Vujanic G; van Tinteren H; van den Heuvel-Eibrink MM; Kool M; de Kraker J; Gisselsson D; Graf N; Gessler M; Pritchard-Jones K
Oncotarget; 2015 Mar; 6(9):7232-43. PubMed ID: 25749049
[TBL] [Abstract][Full Text] [Related]
3. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
[TBL] [Abstract][Full Text] [Related]
4. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.
Williams RD; Al-Saadi R; Chagtai T; Popov S; Messahel B; Sebire N; Gessler M; Wegert J; Graf N; Leuschner I; Hubank M; Jones C; Vujanic G; Pritchard-Jones K; ;
Clin Cancer Res; 2010 Apr; 16(7):2036-45. PubMed ID: 20332316
[TBL] [Abstract][Full Text] [Related]
5. The mycN/max protein complex in neuroblastoma. Short review.
Wenzel A; Schwab M
Eur J Cancer; 1995; 31A(4):516-9. PubMed ID: 7576956
[TBL] [Abstract][Full Text] [Related]
6. Expression and DNA-binding activity of MYCN/Max and Mnt/Max during induced differentiation of human neuroblastoma cells.
Smith AG; Popov N; Imreh M; Axelson H; Henriksson M
J Cell Biochem; 2004 Aug; 92(6):1282-95. PubMed ID: 15258910
[TBL] [Abstract][Full Text] [Related]
7. Targeting of the MYCN protein with small molecule c-MYC inhibitors.
Müller I; Larsson K; Frenzel A; Oliynyk G; Zirath H; Prochownik EV; Westwood NJ; Henriksson MA
PLoS One; 2014; 9(5):e97285. PubMed ID: 24859015
[TBL] [Abstract][Full Text] [Related]
8. MYCN-mediated transcriptional repression in neuroblastoma: the other side of the coin.
Gherardi S; Valli E; Erriquez D; Perini G
Front Oncol; 2013; 3():42. PubMed ID: 23482921
[TBL] [Abstract][Full Text] [Related]
9. MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma.
Ferrucci F; Ciaccio R; Monticelli S; Pigini P; di Giacomo S; Purgato S; Erriquez D; Bernardoni R; Norris M; Haber M; Milazzo G; Perini G
Biochim Biophys Acta Gene Regul Mech; 2018 Mar; 1861(3):235-245. PubMed ID: 29408445
[TBL] [Abstract][Full Text] [Related]
10. Gain of MYCN region in a Wilms tumor-derived xenotransplanted cell line.
Noguera R; Villamón E; Berbegall A; Machado I; Giner F; Tadeo I; Navarro S; Llombart-Bosch A
Diagn Mol Pathol; 2010 Mar; 19(1):33-9. PubMed ID: 20186010
[TBL] [Abstract][Full Text] [Related]
11. Targeting
Liu Z; Chen SS; Clarke S; Veschi V; Thiele CJ
Front Oncol; 2020; 10():623679. PubMed ID: 33628735
[TBL] [Abstract][Full Text] [Related]
12. N-Myc differentially regulates expression of MXI1 isoforms in neuroblastoma.
Armstrong MB; Mody RJ; Ellis DC; Hill AB; Erichsen DA; Wechsler DS
Neoplasia; 2013 Dec; 15(12):1363-70. PubMed ID: 24403858
[TBL] [Abstract][Full Text] [Related]
13. MAX and MYC: a heritable breakup.
Cascón A; Robledo M
Cancer Res; 2012 Jul; 72(13):3119-24. PubMed ID: 22706201
[TBL] [Abstract][Full Text] [Related]
14. The MYCN oncoprotein as a drug development target.
Lu X; Pearson A; Lunec J
Cancer Lett; 2003 Jul; 197(1-2):125-30. PubMed ID: 12880971
[TBL] [Abstract][Full Text] [Related]
15. Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma.
Duffy DJ; Krstic A; Halasz M; Schwarzl T; Fey D; Iljin K; Mehta JP; Killick K; Whilde J; Turriziani B; Haapa-Paananen S; Fey V; Fischer M; Westermann F; Henrich KO; Bannert S; Higgins DG; Kolch W
Oncotarget; 2015 Dec; 6(41):43182-201. PubMed ID: 26673823
[TBL] [Abstract][Full Text] [Related]
16. Biophysical characterization of the b-HLH-LZ of ΔMax, an alternatively spliced isoform of Max found in tumor cells: Towards the validation of a tumor suppressor role for the Max homodimers.
Maltais L; Montagne M; Bédard M; Tremblay C; Soucek L; Lavigne P
PLoS One; 2017; 12(3):e0174413. PubMed ID: 28350847
[TBL] [Abstract][Full Text] [Related]
17. Nmi protein interacts with regions that differ between MycN and Myc and is localized in the cytoplasm of neuroblastoma cells in contrast to nuclear MycN.
Bannasch D; Weis I; Schwab M
Oncogene; 1999 Nov; 18(48):6810-7. PubMed ID: 10597290
[TBL] [Abstract][Full Text] [Related]
18. Molecular Mechanisms of
Liu R; Shi P; Wang Z; Yuan C; Cui H
Front Oncol; 2020; 10():625332. PubMed ID: 33614505
[No Abstract] [Full Text] [Related]
19. The Max transcription factor network: involvement of Mad in differentiation and an approach to identification of target genes.
Hurlin PJ; Ayer DE; Grandori C; Eisenman RN
Cold Spring Harb Symp Quant Biol; 1994; 59():109-16. PubMed ID: 7587059
[TBL] [Abstract][Full Text] [Related]
20. Reconstitution of an E box-binding Myc:Max complex with recombinant full-length proteins expressed in Escherichia coli.
Farina A; Faiola F; Martinez E
Protein Expr Purif; 2004 Apr; 34(2):215-22. PubMed ID: 15003254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
